Mutual Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Mutual Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,607	Closed	-$556K	–	1085
2024 Q1	$556K	Buy	+1,607	New	+$528K	0.02%	662

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Mutual Advisors's BIO Position: Q2 2024 in Review

Mutual Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2024, closing a stake of 1,607 shares — an estimated $556K sold.

Mutual Advisors first reported a position in BIO in Q1 2024 and held it in 1 quarter. The position peaked at $556K in Q1 2024. 439 funds tracked by Wall St. Rank hold BIO as of Q2 2024.

Mutual Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q2 2024 after selling out during the quarter.
Mutual Advisors sold 1,607 Bio-Rad Laboratories Class A shares in Q2 2024, an estimated $556K.
Mutual Advisors first reported a position in Bio-Rad Laboratories Class A in Q1 2024 and held it in 1 quarter.
Mutual Advisors's Bio-Rad Laboratories Class A position peaked at $556K in Q1 2024.
439 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2024.

Based on Mutual Advisors's 13F filing for Q2 2024, filed 30 Jul 2024.